Jefferies Group’s Abiomed Inc ABMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-5,010
Closed -$1.56M 2139
2021
Q2
$1.56M Buy
+5,010
New +$1.54M 0.01% 836
2021
Q1
Sell
-26,820
Closed -$8.7M 2103
2020
Q4
$8.7M Buy
26,820
+18,920
+239% +$5.23M 0.07% 253
2020
Q3
$2.19M Buy
+7,900
New +$2.28M 0.02% 536
2020
Q2
Sell
-4,985
Closed -$743K 2189
2020
Q1
$743K Sell
4,985
-3,572
-42% -$593K 0.01% 1156
2019
Q4
$1.46M Buy
8,557
+5,746
+204% +$1.07M 0.01% 1236
2019
Q3
$500K Buy
+2,811
New +$608K ﹤0.01% 1886
2019
Q2
Sell
-1,000
Closed -$286K 2975
2019
Q1
$286K Buy
+1,000
New +$332K ﹤0.01% 1817
2018
Q4
Sell
-22,657
Closed -$10.2M 2712
2018
Q3
$10.2M Sell
22,657
-13,485
-37% -$5.32M 0.07% 270
2018
Q2
$14.8M Buy
36,142
+25,115
+228% +$9.1M 0.08% 166
2018
Q1
$3.21M Buy
+11,027
New +$2.79M 0.02% 652
2017
Q3
Sell
-2,812
Closed -$403K 2690
2017
Q2
$403K Buy
+2,812
New +$378K ﹤0.01% 1717
2016
Q4
Sell
-6,464
Closed -$831K 2572
2016
Q3
$831K Buy
6,464
+1,564
+32% +$187K ﹤0.01% 1367
2016
Q2
$536K Buy
+4,900
New +$488K ﹤0.01% 1415
2015
Q3
Sell
-3,262
Closed -$214K 3249
2015
Q2
$214K Buy
3,262
+2,749
+536% +$183K ﹤0.01% 1927
2015
Q1
$37K Buy
+513
New +$27.8K ﹤0.01% 1948

Other funds holding ABMD

Jefferies Group's ABMD Position: Q3 2021 in Review

Jefferies Group sold out of Abiomed Inc (ABMD) in Q3 2021, closing a stake of 5,010 shares — an estimated $1.56M sold.

Jefferies Group first reported a position in ABMD in Q1 2015 and held it in 15 quarters. The position peaked at $14.8M in Q2 2018. 498 funds tracked by Wall St. Rank hold ABMD as of Q3 2021.

  • Jefferies Group reported no remaining Abiomed Inc position as of Q3 2021 after selling out during the quarter.
  • Jefferies Group sold 5,010 Abiomed Inc shares in Q3 2021, an estimated $1.56M.
  • Jefferies Group first reported a position in Abiomed Inc in Q1 2015 and held it in 15 quarters.
  • Jefferies Group's Abiomed Inc position peaked at $14.8M in Q2 2018.
  • 498 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2021.

Based on Jefferies Group's 13F filing for Q3 2021, filed 15 Nov 2021.